Skip Navigation
 
 
Printable Version

NADA Number: 011-154

Proprietary Name NFZ® Puffer
Sponsor Neogen Corp.
Sponsor Address 944 Nandino Blvd.
Lexington, KY    40511
USA
Ingredients Nitrofurazone
Species (Class) CATS (DOMESTIC) (Cat, no use class stated or implied)
DOGS (Dog, no use class stated or implied)
EQUIDS (Horse, not for meat production)
Routes of Administration Topical
Opthalmological
Dosage Form Liquid (solution)
Dispensing Status OTC
Dosage Amount,
Indications
& Limitations

524.1580c Nitrofurazone soluble powder.

Specifications: The drug contains 0.2 percent nitrofurazone in a water-soluble base.

Conditions of use:

Dogs

Amount: Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

Indications: For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers and abscesses after incision.

Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation or swelling persists or increases, discontinue use. Consult veterinarian.

Cats

Amount: Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

Indications: For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers and abscesses after incision.

Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation or swelling persists or increases, discontinue use. Consult veterinarian.

Horses

Amount: Apply several times daily to the lesion or affected area from the plastic squeeze bottle.

Indications: For prevention or treatment of surface bacterial infections of wounds, burns, skin ulcers and abscesses after incision.

Limitations. In case of deep or puncture wounds or serious burns, use only as recommended by veterinarian. If redness, irritation or swelling persists or increases, discontinue use. Consult veterinarian. Not for use on horses intended for food.

NAS/NRC status: These conditions are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information.